Literature DB >> 16892063

Exogenous control of mammalian gene expression via modulation of translational termination.

George J Murphy1, Gustavo Mostoslavsky, Darrell N Kotton, Richard C Mulligan.   

Abstract

Here, we describe a system for the exogenous control of gene expression in mammalian cells that relies on the control of translational termination. To achieve gene regulation, we modified protein-coding sequences by introduction of a translational termination codon just downstream from the initiator AUG codon. Translation of the resulting mRNA leads to potent reduction in expression of the desired gene product. Expression of the gene product can be controlled by treating cells that express the mRNA with either aminoglycoside antibiotics or several nonantibiotic compounds. We show that the extent of regulation of gene expression can be substantial (60-fold) and that regulation can be achieved in the case of a variety of different genes, in different cultured cell lines and in primary cells in vivo. This gene regulation strategy offers significant advantages over existing methods for controlling gene expression and should have both immediate experimental application and possible clinical application.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16892063     DOI: 10.1038/nm1376

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  32 in total

Review 1.  A shift from cell cultures to creatures: in vivo imaging of small animals in experimental regenerative medicine.

Authors:  Anna J Studwell; Darrell N Kotton
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

2.  Quantitative analysis of cell tracing by in vivo imaging system.

Authors:  Junmeng Zheng; Lijun Xu; Hongmin Zhou; Weina Zhang; Zhonghua Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-08-17

3.  Identification and proteomic analysis of distinct UBE3A/E6AP protein complexes.

Authors:  Gustavo Martínez-Noël; Jeffrey T Galligan; Mathew E Sowa; Verena Arndt; Thomas M Overton; J Wade Harper; Peter M Howley
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

4.  Screening for engineered neomycin riboswitches that control translation initiation.

Authors:  Julia E Weigand; Martin Sanchez; Ewald-Bernd Gunnesch; Sabrina Zeiher; Renee Schroeder; Beatrix Suess
Journal:  RNA       Date:  2007-11-13       Impact factor: 4.942

5.  CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.

Authors:  J Dawn Waters; Carlos Sanchez; Ayguen Sahin; Diahnn Futalan; David D Gonda; Justin K Scheer; Johnny Akers; Kamalakannan Palanichamy; Peter Waterman; Arnab Chakravarti; Ralph Weissleder; Brent Morse; Nick Marsh; Eric Furfine; Clark C Chen; Irvith Carvajal; Bob S Carter
Journal:  J Neurooncol       Date:  2012-08-09       Impact factor: 4.130

6.  Activation dynamics and signaling properties of Notch3 receptor in the developing pulmonary artery.

Authors:  Shamik Ghosh; Jesus R Paez-Cortez; Karthik Boppidi; Michelle Vasconcelos; Monideepa Roy; Wellington Cardoso; Xingbin Ai; Alan Fine
Journal:  J Biol Chem       Date:  2011-05-02       Impact factor: 5.157

7.  Post-transcriptional control of Na,K-ATPase activity and cell growth by a splice variant of FXYD2 protein with modified mRNA.

Authors:  Kathleen J Sweadner; Jennifer L Pascoa; Cynthia A Salazar; Elena Arystarkhova
Journal:  J Biol Chem       Date:  2011-04-01       Impact factor: 5.157

8.  Post-transcriptionally regulated expression system in human xenogeneic transplantation models.

Authors:  Hui-Ling Rose Lee; Chiann-Chyi Chen; Timor Baasov; Yacov Ron; Joseph P Dougherty
Journal:  Mol Ther       Date:  2011-05-17       Impact factor: 11.454

9.  The effect of gentamicin-induced readthrough on a novel premature termination codon of CD18 leukocyte adhesion deficiency patients.

Authors:  Amos J Simon; Atar Lev; Baruch Wolach; Ronit Gavrieli; Ninette Amariglio; Ester Rosenthal; Ephraim Gazit; Eran Eyal; Gideon Rechavi; Raz Somech
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

10.  Genetically engineered T cells to target EGFRvIII expressing glioblastoma.

Authors:  Szofia S Bullain; Ayguen Sahin; Oszkar Szentirmai; Carlos Sanchez; Ning Lin; Elizabeth Baratta; Peter Waterman; Ralph Weissleder; Richard C Mulligan; Bob S Carter
Journal:  J Neurooncol       Date:  2009-04-23       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.